{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T01:45:50Z","timestamp":1761788750642},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2004,8,7]],"date-time":"2004-08-07T00:00:00Z","timestamp":1091836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1007\/s00198-004-1710-6","type":"journal-article","created":{"date-parts":[[2004,8,6]],"date-time":"2004-08-06T16:06:42Z","timestamp":1091808402000},"page":"490-500","source":"Crossref","is-referenced-by-count":12,"title":["Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study"],"prefix":"10.1007","volume":"16","author":[{"given":"Deborah","family":"Layton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynda V.","family":"Wilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad A. W.","family":"Shakir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,8,7]]},"reference":[{"key":"CR1","unstructured":"World Health Organisation (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group, Report No. 843"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1056\/NEJM200202283460902","volume":"346","author":"Solomon","year":"2002","unstructured":"Solomon CG (2002) Bisphosphonates and osteoporosis. N Engl J Med 346:642","journal-title":"N Engl J Med"},{"key":"CR3","first-page":"the","volume":"women","author":"Hannan","year":"2000","unstructured":"Hannan MT, Felson DT, Dawson-Hughes B, Tucker KL, Cupples LA, Wilson PW et al. (2000) Risk factors for longitudinal bone loss in elderly men and women: the Framingham Osteoporosis Study. J Bone Miner Res 15710\u2013720","journal-title":"Risk factors for longitudinal bone loss in elderly men and"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1098-3597(00)90001-2","volume":"2","author":"Raisz","year":"2000","unstructured":"Raisz LG, Prestwood KM (2000) Epidemiology and pathogenesis of osteoporosis. Clin Cornerstone 2:1\u201310","journal-title":"Clin Cornerstone"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0025-7125(16)30163-8","volume":"78","author":"Putukian","year":"1994","unstructured":"Putukian M (1994) The female triad. Eating disorders, amenorrhea, and osteoporosis. Med Clin N Am 78:345\u2013356","journal-title":"Med Clin N Am"},{"key":"CR6","first-page":"224","volume":"281","author":"Centers","year":"1999","unstructured":"Centers for Disease Control and Prevention (1999) Osteoporosis among estrogen-deficient women\u2014United States, 1988\u20131994. JAMA 281:224\u2013226","journal-title":"JAMA"},{"key":"CR7","doi-asserted-by":"crossref","unstructured":"van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39:1383\u20131389","DOI":"10.1093\/rheumatology\/39.12.1383"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1056\/NEJM199803123381107","volume":"338","author":"Eastell","year":"1998","unstructured":"Eastell R (1998) Treatment of postmenopausal osteoporosis. N Engl J Med 338:736\u2013746","journal-title":"N Engl J Med"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0140-6736(96)07365-5","volume":"349","author":"Beresford","year":"1997","unstructured":"Beresford SA, Weiss NS, Voigt LF, McKnight B (1997) Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 349:458\u2013461","journal-title":"Lancet"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jama.288.3.334","volume":"288","author":"Lacey","year":"2002","unstructured":"Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P et al. (2002) Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288:334\u2013341","journal-title":"JAMA"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0140-6736(97)08233-0","volume":"350","author":"Collaborative","year":"1997","unstructured":"Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047\u20131059","journal-title":"Lancet"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1001\/jama.283.4.485","volume":"283","author":"Schairer","year":"2000","unstructured":"Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283:485\u2013491","journal-title":"JAMA"},{"key":"CR13","doi-asserted-by":"crossref","unstructured":"Women\u2019s Health Initiative randomized controlled trial (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results JAMA 288:321\u2013333","DOI":"10.1001\/jama.288.3.321"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S0140-6736(02)11032-4","volume":"360","author":"Beral","year":"2002","unstructured":"Beral V, Banks E, Reeves G (2002) Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 360:942\u2013944","journal-title":"Lancet"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0140-6736(96)24041-3","volume":"348","author":"Daly","year":"1996","unstructured":"Daly E, Vessey MP, Painter R, Hawkins MM (1996) Case-control study of venous thromboembolism risk in users of hormone replacement therapy. Lancet 348:1027","journal-title":"Lancet"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/00002018-199818020-00003","volume":"18","author":"Castellsague","year":"1998","unstructured":"Castellsague J, Perez GS, Garcia Rodriguez LA (1998) Recent epidemiological studies of the association between hormone replacement therapy and venous thromboembolism. A review. Drug Saf 18:117\u2013123","journal-title":"Drug Saf"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/0003-4819-132-9-200005020-00002","volume":"132","author":"Grady","year":"2000","unstructured":"Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D et al. (2000) Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen\/progestin Replacement Study. Ann Intern Med 132:689\u2013696","journal-title":"Ann Intern Med"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jama.288.1.58","volume":"288","author":"Hulley","year":"2002","unstructured":"Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W et al. (2002) Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen\/progestin Replacement Study follow-up (HERS II). JAMA 288:58\u201366","journal-title":"JAMA"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0140-6736(96)07114-0","volume":"348","author":"Jick","year":"1996","unstructured":"Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM (1996) Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 348:981\u2013983","journal-title":"Lancet"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jama.280.7.605","volume":"280","author":"Hulley","year":"1998","unstructured":"Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen\/progestin Replacement Study (HERS) Research Group. JAMA 280:605\u2013613","journal-title":"JAMA"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"Rossouw","year":"2002","unstructured":"Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u201ds Health Initiative randomized controlled trial. JAMA 288:321\u2013333","journal-title":"JAMA"},{"key":"CR22","first-page":"Evista","volume":"Characteristics","author":"Eli","year":"1998","unstructured":"Eli Lilly and Company Limited (1998) Summary of Product Characteristics: Evista 60 tablets","journal-title":"Summary of Product"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1093\/ajhp\/57.18.1669","volume":"57","author":"Snyder","year":"2000","unstructured":"Snyder KR, Sparano N, Malinowski JM (2000) Raloxifene hydrochloride. Am J Health Syst Pharm 57:1669\u20131675","journal-title":"Am J Health Syst Pharm"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1023\/A:1010019410881","volume":"2","author":"Bryant","year":"2001","unstructured":"Bryant HU (2001) Mechanism of action and preclinical profile of raloxifene, a selective estrogen receptor modulation. Rev Endocr Metab Disord 2:129\u2013138","journal-title":"Rev Endocr Metab Disord"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2165\/00003495-200060020-00013","volume":"60","author":"Clemett","year":"2000","unstructured":"Clemett D, Spencer CM (2000) Raloxifene: a review of its use in postmenopausal osteoporosis. Drugs 60:379\u2013411","journal-title":"Drugs"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1136\/dtb.1999.37533","volume":"37","author":"Anon","year":"1999","unstructured":"Anon (1999) Raloxifene to prevent postmenopausal osteoporosis. Drug Ther Bull 37:33\u201336","journal-title":"Drug Ther Bull"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637\u2013645","journal-title":"JAMA"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1359\/jbmr.1998.13.11.1747","volume":"13","author":"Lufkin","year":"1998","unstructured":"Lufkin EG, Whitaker MD, Nickelsen T, Argueta R, Caplan RH, Knickerbocker RK et al. (1998) Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 13:1747\u20131754","journal-title":"J Bone Miner Res"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s001980050236","volume":"10","author":"Meunier","year":"1999","unstructured":"Meunier PJ, Vignot E, Garnero P, Confavreux E, Paris E, Liu-Leage S et al. (1999) Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group. Osteoporos Int 10:330\u2013336","journal-title":"Osteoporos Int"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","volume":"337","author":"Delmas","year":"1997","unstructured":"Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ et al. (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641\u20131647","journal-title":"N Engl J Med"},{"key":"CR31","first-page":"3425","volume":"82","author":"Heaney","year":"1997","unstructured":"Heaney RP, Draper MW (1997) Raloxifene and estrogen: comparative bone-remodeling kinetics. J Clin Endocrinol Metab 82:3425\u20133429","journal-title":"J Clin Endocrinol Metab"},{"key":"CR32","doi-asserted-by":"crossref","unstructured":"Shakir SA (2002) PEM in the UK. In: Mann RD, Andrews E (eds) Pharmacovigilance, 1st edn. Wiley, Chichester, pp\u00a0333\u2013344","DOI":"10.1002\/0470853093.ch26"},{"key":"CR33","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1163\/157180994X00268","volume":"1","author":"Legemaate","year":"1994","unstructured":"Legemaate J (1994) The CIOMS guidelines for biomedical research involving human subjects. Eur J Health Law 1:161\u2013165","journal-title":"Eur J Health Law"},{"key":"CR34","unstructured":"Royal College of Physicians of London (1996) Guidelines on the practice of ethical committees in medical research involving human subjects. RCOP, London, UK"},{"key":"CR35","unstructured":"Multi-Centre Research Ethics Committees Guidance Notes (2000) Examples of enquiries and surveys in the public interest where no reference to a Research Ethics Committee is necessary. Web address: http:\/\/www.corec.org.uk\/wordDocs\/Guidenotes.doc"},{"key":"CR36","unstructured":"Shakir SAW (2004) Causality and correlation in pharmacovigilance. In: Talbot J, Waller PC (eds) Stephens\u2019 detection of new adverse drug reactions, 5th edn. Wiley, Chichester, pp\u00a0329\u2013343"},{"key":"CR37","first-page":"1","volume":"6","author":"Stephens","year":"1987","unstructured":"Stephens MD (1987) The diagnosis of adverse medical events associated with drug treatment. Adverse Drug React Acute Poisoning Rev 6:1\u201335","journal-title":"Adverse Drug React Acute Poisoning Rev"},{"key":"CR38","unstructured":"Machin D, Campbell M, Fayers P et al. (1997) Sample size tables for clinical studies, Table\u00a07.1. Blackwell Science, Oxford"},{"key":"CR39","unstructured":"Machin D, Campbell M, Fayers P et al. (1997) Sample size tables for clinical studies, Table\u00a07.2. Blackwell Science, Oxford"},{"key":"CR40","first-page":"558","volume":"93","author":"Davies","year":"1999","unstructured":"Davies GC, Huster WJ, Lu Y, Plouffe L Jr, Lakshmanan M (1999) Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 93:558\u2013565","journal-title":"Obstet Gynecol"},{"key":"CR41","doi-asserted-by":"crossref","unstructured":"Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189\u20132197","DOI":"10.1001\/jama.281.23.2189"},{"key":"CR42","first-page":"Evista","volume":"Characteristics","author":"Eli","year":"2001","unstructured":"Eli Lilly and Company Limited (2001) Summary of Product Characteristics: Evista 60\u00a0mg tablets","journal-title":"Summary of Product"},{"key":"CR43","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/jama.287.7.847","volume":"287","author":"Barrett-Connor","year":"2002","unstructured":"Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K et al. (2002) Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287:847\u2013857","journal-title":"JAMA"},{"key":"CR44","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/S0140-6736(01)06898-2","volume":"358","author":"Heeley","year":"2001","unstructured":"Heeley E, Riley J, Layton D, Wilton LV, Shakir SA (2001) Prescription-event monitoring and reporting of adverse drug reactions. Lancet 358:1872\u20131873","journal-title":"Lancet"},{"key":"CR45","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/bmj.313.7059.732","volume":"313","author":"McAvoy","year":"1996","unstructured":"McAvoy BR, Kaner EF (1996) General practice postal surveys: a questionnaire too far? BMJ 313:732\u2013733","journal-title":"BMJ"},{"key":"CR46","first-page":"91","volume":"47","author":"Templeton","year":"1997","unstructured":"Templeton L, Deehan A, Taylor C, Drummond C, Strang J (1997) Surveying general practitioners: does a low response rate matter? Br J Gen Pract 47:91\u201394","journal-title":"Br J Gen Pract"},{"key":"CR47","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/pds.690","volume":"11","author":"Key","year":"2002","unstructured":"Key C, Layton D, Shakir SA (2002) Results of a postal survey of the reasons for non-response by doctors in a Prescription Event Monitoring study of drug safety. Pharmacoepidemiol Drug Saf 11:143\u2013148","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"CR48","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jama.279.18.1445","volume":"279","author":"Walsh","year":"1998","unstructured":"Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB et al. (1998) Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279:1445\u20131451","journal-title":"JAMA"},{"key":"CR49","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2165\/00003495-199753030-00006","volume":"53","author":"Jeal","year":"1997","unstructured":"Jeal W, Barradell LB, McTavish D (1997) Alendronate. A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis. Drugs 53:415\u2013434","journal-title":"Drugs"},{"key":"CR50","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00198-003-1399-y","volume":"14","author":"Biswas","year":"2003","unstructured":"Biswas PN, Wilton LV, Shakir SA (2003) Pharmacovigilance study of alendronate in England. Osteoporos Int 14:507\u2013514","journal-title":"Osteoporos Int"},{"key":"CR51","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/jbmr.5650110615","volume":"11","author":"Draper","year":"1996","unstructured":"Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C (1996) A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 11:835\u2013842","journal-title":"J Bone Miner Res"},{"key":"CR52","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/00042192-199906030-00003","volume":"6","author":"Davies","year":"1999","unstructured":"Davies GC, Huster WJ, Shen W, Mitlak B, Plouffe L Jr, Shah A et al. (1999) Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women. Menopause 6:188\u2013195","journal-title":"Menopause"},{"key":"CR53","doi-asserted-by":"crossref","unstructured":"Boss SM, Huster WJ, Neild JA, Glant MD, Eisenhut CC, Draper MW. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 177:1458\u20131464","DOI":"10.1016\/S0002-9378(97)70091-7"},{"key":"CR54","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/jnci\/92.4.328","volume":"92","author":"Ross","year":"2000","unstructured":"Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92:328\u2013332","journal-title":"J Natl Cancer Inst"},{"key":"CR55","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(03)14596-5","volume":"362","author":"Beral","year":"2003","unstructured":"Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419\u2013427","journal-title":"Lancet"},{"key":"CR56","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jama.288.7.872","volume":"288","author":"Nelson","year":"2002","unstructured":"Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD (2002) Postmenopausal hormone replacement therapy: scientific review. JAMA 288:872\u2013881","journal-title":"JAMA"},{"key":"CR57","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1365-2125.2003.01953.x","volume":"57","author":"Martin","year":"2004","unstructured":"Martin K, Begaud B, Latry P, Miremont-Salame G, Fourrier A, Moore N (2004) Differences between clinical trials and postmarketing use. Br J Clin Pharmacol 57:86\u201392","journal-title":"Br J Clin Pharmacol"},{"key":"CR58","first-page":"14","volume":"20","author":"Anon","year":"2001","unstructured":"Anon (2001) Raloxifene and thromboembolic events. Aust Adv Drug Reactions Bull 20:14\u201315","journal-title":"Aust Adv Drug Reactions Bull"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-004-1710-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-004-1710-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-004-1710-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T23:14:53Z","timestamp":1585869293000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-004-1710-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,7]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["1710"],"URL":"https:\/\/doi.org\/10.1007\/s00198-004-1710-6","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8,7]]}}}